Ergo Science submits NDA for Ergoset bromocriptine for type 2 diabetes.
Executive Summary
ERGO SCIENCE SUBMITS ERGOSET NDA FOR TYPE 2 DIABETES AUG. 22, based on three pivotal trials in 600 obese non-insulin dependent diabetic patients. The Phase III studies cover the use of Ergoset (bromocriptine) as monotherapy and in conjunction with sulfonylureas. Ergoset is a low-dose fast-release form of the D2 dopamine agonist, which is primarily used in the treatment of Parkinson's disease.